Please ensure Javascript is enabled for purposes of website accessibility
Accueil > Products > Anticorps > Biosimilaires

Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO) (HF879026)

Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)
Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)
Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)
Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)
Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)
Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)
Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)
Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)
Prix(USD) :
Spécification :
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Nombre :
Contactez-nous
  • Aperçu

  • Images

  • Reférences

  • Fiche technique

  • SDS

Aperçu
Numéro de catalogueHF879026
Reactivité des espècesHuman
ApplicationsELISA, Bioactivity: FCM, Functional assay, Research in vivo
Espèce hôteHuman
ClonalitéMonoclonal
IsotypeIgG1, kappa
Activité biologique Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study [2]. The elimination half-life (t 1/2) of Adalimumab is long (~20 days) [1]. The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr -/- mice [2].
Applications testées FCM
Cible C-domain 1, C-domain 2, Cachectin, ICD1, ICD2, Intracellular domain 1, Intracellular domain 2, N-terminal fragment, NTF, TNF, TNF-a, TNF-alpha, TNFA, TNFSF2, Tumor necrosis factor, Tumor necrosis factor ligand superfamily member 2, Tumor necrosis factor, membrane form, Tumor necrosis factor, soluble form
Niveau d'endotoxines < 10 EU/mg
Pureté >95% as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Numéro d'accès P01375
Forme Liquid
Tampon de stockage 0.01M PBS pH 7.4.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Stabilité et stockage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifsABP501, D2E7, Adalimumab, AdalimumabBeta, 331731-18-1
Contexte

Tumor necrosis factor (TNFa/TNF-alpha) is a ~25 kDa protein. Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. TNFa is the therapeutic target of adalimumab (Humira).

1. Nie, H. et al. (2013) Nature medicine 19, 322-8. PMID: 23396208
2. Friedmann, E. et al. (2006) Nature cell biology 8, 843-8. PMID: 16829952
3. Jinesh G, G. et al. (2012) Journal of leukocyte biology 92, 233-44. PMID: 22517918
4. Nakahara, H. et al. (2003) Arthritis and rheumatism 48, 1521-9. PMID: 12794819
Reférences 1. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97. [HF879026]
2. Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145. [HF879026]
Note For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)
Images
  • Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)

    SEC-HPLC

    SEC-HPLC detection for Research Grade Adalimumab.

  • Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)

    Bioactivity

    Detects Human TNFa/TNF-alpha in indirect ELISAs.

  • Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)

    Flow Cytometry

    Flow-cytometry using anti-human TNFa antibody. 293T Transtected cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human TNFa monoclonal antibody (Catalog HF879026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.

  • Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Adalimumab.

Reférences
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : [email protected]

Liste des distributeurs